TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 0.130nMAssay Description:Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and infected with T7 ph...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 0.200nMAssay Description:Inhibition of KDR by cellular assayMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 0.230nMAssay Description:Average Binding Constant for VEGFR2; NA=Not Active at 10 uMMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 0.380nMAssay Description:A competition binding assay, was used to measure the ability of a compound to compete for binding of an immobilized adenosine triphosphate (ATP) site...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 1nMAssay Description:Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and infected with T7 ph...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: <1nMAssay Description:Binding affinity to of human partial length VGFR2 expressed in mammalian system by active site-directed competition binding assayMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 1.10nMAssay Description:Binding constant for VEGFR2 kinase domainMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 1.5nMAssay Description:Binding constant for VEGFR2 kinase domainMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 1.5nMAssay Description:Binding constant for VEGFR2 kinase domainMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 1.5nMAssay Description:Binding affinity to VEGFR2More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 1.5nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 2.10nMAssay Description:Binding affinity to VEGFR2 (unknown origin) by proteros reporter displacement assayMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 2.30nMAssay Description:Binding constant for VEGFR2 kinase domainMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 2.30nMAssay Description:Binding constant for VEGFR2 kinase domainMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 2.30nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 2.90nMpH: 7.0 T: 2°CAssay Description:KDR (h) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.33 mg/mL myelin basic protein, 10 mM MgAcetate and [.gamma.-.sup.33P-ATP] (specific activi...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 2.90nMAssay Description:Binding constant for VEGFR2 kinase domainMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 3.20nMpH: 7.0 T: 2°CAssay Description:KDR (h) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.33 mg/mL myelin basic protein, 10 mM MgAcetate and [.gamma.-.sup.33P-ATP] (specific activi...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 5nMAssay Description:Binding constant for VEGFR2 kinase domainMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 5.90nMAssay Description:Binding constant for VEGFR2 kinase domainMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 6.30nMpH: 7.0 T: 2°CAssay Description:KDR (h) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.33 mg/mL myelin basic protein, 10 mM MgAcetate and [.gamma.-.sup.33P-ATP] (specific activi...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 7.90nMAssay Description:Binding affinity to VEGFR2 (unknown origin) assessed as dissociation constant measured by ambit kinomescan assayMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 8nMAssay Description:Inhibition of VEGFR2 in human HEK293 cells after 1 hr by competition binding assayMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 8.10nMAssay Description:Binding constant for VEGFR2 kinase domainMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 8.10nMAssay Description:Binding constant for VEGFR2 kinase domainMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 8.10nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 12nMAssay Description:Binding constant for VEGFR2 kinase domainMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 14nMAssay Description:Binding constant for VEGFR2 kinase domainMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 14nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 14nMAssay Description:Binding constant for VEGFR2 kinase domainMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 16nMAssay Description:Competitive inhibition of VEGFR2 by qPCR methodMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 18nMAssay Description:Binding constant for VEGFR2 kinase domainMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 19nMAssay Description:Binding affinity to human N-terminal His-tagged non-phosphorylated VEGFR2 by surface plasmon resonance analysisMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 20nMAssay Description:Binding affinity to DNA-tagged VEGFR2 by qPCR based competitive binding assayMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 26nMAssay Description:Binding constant for VEGFR2 kinase domainMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 26nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 26nMAssay Description:Binding constant for VEGFR2 kinase domainMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ashvattha Therapeutics
US Patent
Ashvattha Therapeutics
US Patent
Affinity DataKd: 27nMAssay Description:Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and infected with T7 ph...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info